View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

CEA Industries Inc. Reports Fourth Quarter and Full Year 2023 Results

CEA Industries Inc. Reports Fourth Quarter and Full Year 2023 Results Louisville, Colorado, March 28, 2024 (GLOBE NEWSWIRE) -- CEA Industries Inc. (NASDAQ: CEAD, CEADW) (“CEA Industries” or the “Company”), is reporting results for the three and twelve months ended December 31, 2023. Fourth Quarter 2023 Financial Summary (in $ thousands, excl. margin items):  Q4 2023(unaudited)Q3 2023(unaudited)Q4 2022(unaudited)Revenue$251 $914 $1,461 Gross Profit$(286)$(104)$151 Gross Margin (113.8%) (11.4%) 10.3%Operating Expenses$709 $703 $1,433 Net Income/(Loss)$(988)$(799)$(1,272) Full Year 2023 F...

 PRESS RELEASE

AGBA Announces Fourth Quarter 2023 Earnings, Amid Challenging Macro En...

AGBA Announces Fourth Quarter 2023 Earnings, Amid Challenging Macro Environment. HONG KONG, March 28, 2024 (GLOBE NEWSWIRE) -- NASDAQ-listed, AGBA Group Holding Limited (“AGBA” or “the Company”) the leading one-stop financial supermarket in Hong Kong released its financial results for the fourth quarter of 2023. The Company generated $48.9 million in commissions from its Distribution Business during the fourth quarter of 2023, which is double the figure generated during the same period in 2022. This substantial improvement reflects the company's progress. However, the company believe...

 PRESS RELEASE

Power Solutions International Announces Extension to Credit Agreement

Power Solutions International Announces Extension to Credit Agreement WOOD DALE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Power Solutions International, Inc. (the “Company” or “PSI”) amended its $130 million uncommitted senior secured revolving credit agreement (the “Fourth Amended and Restated Credit Agreement”), with Standard Chartered Bank, as administrative agent (“Standard Chartered”), and the lenders party thereto from time to time. The Fourth Amended and Restated Credit Agreement extends the maturity date of loans outstanding under its previous credit facility to the earlier of Mar...

 PRESS RELEASE

Forian Inc. Announces Fourth Quarter and Full Year 2023 Financial Resu...

Forian Inc. Announces Fourth Quarter and Full Year 2023 Financial Results Full Year 2023 Revenue Grew 25% Full Year 2023 Adjusted EBITDA of $2.3MM NEWTOWN, PA, March 28, 2024 (GLOBE NEWSWIRE) -- via -- Forian Inc. (Nasdaq: FORA), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, today announced results for the quarter and year ended December 31, 2023. “Forian finished the year by executing against our quarterly plan and closed what was a transformational year,” stated Max Wygod, Chairman and Chief Exe...

 PRESS RELEASE

Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports F...

Oxford: Owner of Tommy Bahama, Lilly Pulitzer and Johnny Was Reports Fourth-Quarter and Full-Year Fiscal 2023 Results; Posts 11% Annual Sales Growth; Announces 3% Increase in Quarterly Dividend Full-year sales increased 11% to $1.57 billionFiscal 2023 GAAP EPS of $3.82 impacted by noncash impairment charges of $5.32 per share. Adjusted EPS of $10.15, within guidance rangeInitiates fiscal 2024 guidance of revenues of $1.630 billion to $1.670 billion, GAAP EPS of $8.80 to $9.20 and adjusted EPS of $9.30 to $9.70 ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Oxford Industries, Inc. (NYSE:...

 PRESS RELEASE

Revolution Medicines to Deliver Multiple Presentations at the Upcoming...

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024 REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California. Details of the planned presentation...

 PRESS RELEASE

Fortress Biotech Reports 2023 Financial Results and Recent Corporate H...

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application filing for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults; PDUFA goal date of November 4, 2024 MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term va...

 PRESS RELEASE

TPI Composites, Inc. Publishes its Annual Sustainability Report Reaffi...

TPI Composites, Inc. Publishes its Annual Sustainability Report Reaffirming Its Commitments to a Zero-Harm Culture and Carbon Neutrality SCOTTSDALE, Ariz., March 28, 2024 (GLOBE NEWSWIRE) -- TPI Composites, Inc. (Nasdaq: TPIC), today published its 2023 sustainability report highlighting its progress on organizational and global impacts related to sustainability. Bill Siwek, President, and CEO noted, “Providing the means necessary for the world to embrace renewable energy and reduce reliance on fossil fuels is the foundation of our company and we are dedicated to doing so responsibly. W...

 PRESS RELEASE

ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer

ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer ASML cautions investors regarding Tutanota LLC’s “mini-tender” offer VELDHOVEN, the Netherlands, March 28, 2024 – ASML Holding NV (ASML) today announced that it recently became aware of an unsolicited “mini-tender” offer by Tutanota LLC to purchase up to 250,000 (two hundred and fifty thousand) of ASML’s ordinary shares, nominal value €0.09 per share, representing significantly less than 0.1% of ASML’s ordinary shares, at an offer price of $1,075 net per share. ASML is not associated in any way with Tutanota or i...

 PRESS RELEASE

Leading Proxy Advisory Firms Recommend ContextLogic Stockholders Vote ...

Leading Proxy Advisory Firms Recommend ContextLogic Stockholders Vote “FOR” Pending Transaction with Qoo10 ISS, Glass Lewis and Egan-Jones Endorse Proposed Transaction Stockholders are Encouraged to Vote FOR the Value-Maximizing Transaction Before the Electronic Proxy Voting Deadline of 11:59 P.M. Eastern Time on Thursday, April 11, 2024 SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (d/b/a Wish) (NASDAQ: WISH) (“ContextLogic” or the “Company”) today announced that proxy advisory firms Institutional Shareholder Services (“ISS”), Glass Lewis and Egan-Jones have all r...

 PRESS RELEASE

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial...

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update Positive Business Momentum and Sales Pipeline Growth Following FDA 510(k) Clearance of Vivos’ Proprietary Oral Medical Devices to Treat Severe Obstructive Sleep Apnea Annual Operating Expenses Declined 27% Due to Success of Cost Cutting Initiatives Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company special...

 PRESS RELEASE

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase...

Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced it will host a webcast on Thursday, April 11, 2024, at 8:00 a.m. ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia...

 PRESS RELEASE

Acuity Brands Declares Quarterly Dividend

Acuity Brands Declares Quarterly Dividend Atlanta, March 28, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of (NYSE: AYI; "Company") today declared a quarterly dividend of 15 cents per share. The dividend is payable on May 1, 2024, to shareholders of record on April 17, 2024. About Acuity Brands Acuity Brands, Inc. (NYSE: AYI) is a market-leading industrial technology company. We use technology to solve problems in spaces, light, and more things to come. Through our two business segments, Acuity Brands Lighting and Lighting Controls (ABL) and the Intelligent Spaces Group (ISG), we de...

 PRESS RELEASE

Candel Therapeutics Announces Oral Presentation During the 5th Gliobla...

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma The first cohort of patients were treated with multiple injections of CAN-3110 in the ongoing phase 1b clinical trial.The serial procedures were well tolerated without observed dose-limiting toxicity.A second cohort is being planned for enrollment in the ongoing phase 1b clinical trial of CAN-3110. NEEDHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CA...

 PRESS RELEASE

Femasys Announces Financial Results for Year Ended December 31, 2023 a...

Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update Following FDA Clearance of FemaSeed®, Company Secures Capital to Support Commercial Initiatives; Cash Expected to Fund Operations Into 2H 2025 ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the year ended December 31, 2023 and provides a corp...

 PRESS RELEASE

Ardelyx, Inc. Reports Employment Inducement Grants

Ardelyx, Inc. Reports Employment Inducement Grants WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on March 25, 2024, the compensation committee of the company’s board of directors granted a non-qualified stock option award to purchase 205,000 shares of its common stock and a restricted stock unit award for 160,000 shares in connection with the commencement of employme...

 PRESS RELEASE

Global-e Announces Filing of Form 20-F for the Fiscal Year Ended Decem...

Global-e Announces Filing of Form 20-F for the Fiscal Year Ended December 31, 2023 PETAH-TIKVA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Global-e Online Ltd. (Nasdaq: GLBE) the leader of global Direct-To-Consumer ecommerce enablement, announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission. The annual report on Form 20-F can be accessed on the Company’s investors relations website at  or on the SEC’s website at . Global-e will provide a hard copy of the annual report containing its audited fina...

 PRESS RELEASE

CGRA Announces Completion and Publication of 2023 Annual Disclosure

CGRA Announces Completion and Publication of 2023 Annual Disclosure NEW YORK, NY, March 28, 2024 (GLOBE NEWSWIRE) -- via -- CGrowth Capital Inc. (OTC: CGRA) is a public holding company for alternative and undervalued assets. The company is sector and industry agnostic and currently consists of two divisions including Mining and Sports Technology. The company is focused on investing in growth-oriented opportunities where the company’s capital, expertise, and capabilities can help create significant added value for shareholders. CGRA is pleased to announce the completion and publicati...

 PRESS RELEASE

Dorchester Minerals, L.P. Announces Acquisition of Mineral Interests

Dorchester Minerals, L.P. Announces Acquisition of Mineral Interests DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today it completed an acquisition of mineral interests totaling approximately 1,485 net royalty acres located in two counties in Colorado. The transaction was structured as a non-taxable contribution and exchange. The contributing entities conveyed their interests to the Partnership in exchange for 505,369 common units representing limited partnership interests in Dorchester Minerals, L.P. Dorchester Mineral...

 PRESS RELEASE

Paragon 28 Adds to Suite of Novel Syndesmosis Repair Solutions with La...

ENGLEWOOD, Colo.--(BUSINESS WIRE)-- Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Grappler® R3INFORCE™ Extraosseous Repair System designed to restore stability to the anterior and posterior ligaments surrounding the ankle during fibula fracture repairs and high ankle sprains. This press release features multimedia. View the full release here: Figure 1: Anterior inferior tibiofibular ligament (“AITFL”) Repair Showing the Grappler® R3INFORCE™ Dynamic Anchor (left) and Grappler® Knotless Anchor (center). Complete Extraosseous Repair with Grappler® R3INFORCE™ System shown...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch